Company Profile

Glannaventa Inc
Profile last edited on: 2/9/2023      CAGE: 6TV17      UEI: V4XEE6EK5LH6

Business Identifier: Point-of-care early stage ovarian cancer diagnosis
Year Founded
2010
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2276 Allegheny Way
San Mateo, CA 94402
   (650) 274-2081
   N/A
   www.glannaventa.com
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

Glannaventa, Inc., is an early-stage medical device company structured around development of an outpatient / point-of-care endoscopic screening test for a silent killer of women :ovarian cancer. As individuals and as a team, the principals at Glannaventa have experience in development of lasers, optics, biophotonics, and image-guided surgery -- including realizing the first real-time, OCT-guided therapeutic surgical procedure in humans and the development of a revolutionary new treatment for cutaneous vascular lesions

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $399,331
Project Title: Outpatient Screening for Early-Stage High-Grade Serous Ovarian Cancer in Higher Risk Women

Key People / Management

  John Black -- Founder, President and CEO

Company News

There are no news available.